LARGO, Fla., March 15 /PRNewswire-FirstCall/ -- Mr. Jugal K. Taneja, Chairman of the Board of GeoPharma, Inc. , a rapidly growing manufacturer of pharmaceutical products, is pleased to announce that Dr. Rafick Henein has agreed to join the company's Board of Directors.
Dr. Henein brings a wealth of international pharmaceutical business leadership to the position. Dr. Henein holds a PhD in pharmaceutical technology from the Academy of Sciences of Hungary and a MSc in pharmaceutical sciences from the Budapest University of Medicine in Hungary. He also has a MBA and a Diploma of Management from McGill University in Montreal, Quebec, Canada. A graduate of the Faculty of Pharmacy, Cairo University, Dr. Henein is a member of the Ontario College of Pharmacists and the Order of Pharmacists of Quebec.
Dr. Henein has held various executive positions in the pharmaceutical industry in the Middle East, Europe, Canada and the United States. In Canada, he started his career at Ayerst Laboratories, Inc. in 1971 and served as Senior Vice President, Plant and Distribution Operations from 1983 to 1988. He then joined Novopharm Limited (Canada), first as Executive Vice President, and subsequently as President and Chief Operating Officer before being named President and Chief Executive Officer of Novopharm International. In 1997, Dr. Henein joined IVAX Pharmaceuticals Inc., a leading generic company headquartered in Miami, Florida and served as its President and Chief Executive Officer until its acquisition last year by Teva to form one of the largest generic pharmaceutical companies in the world.
"Dr. Henein's vast international industry expertise and entrepreneurial success make him an outstanding addition to the Board," said Mr. Taneja, Chairman of the Board. "With over forty years of pharmaceutical experience, he will accelerate our company's growth over the coming years."
Dr. Henein said, "Jugal and Mihir Taneja's leadership will allow GeoPharma to become one of the leading generic pharmaceutical companies in the United States. We will be a tough team to beat."
GeoPharma, Inc. is a rapidly growing pharmaceutical company specializing in the manufacturing and distribution of over-the-counter, nutritional, generic drug and functional food products. The company's growth strategy is to capitalize on its manufacturing expertise to develop high margin generic or novel drugs for niche markets with high barriers to entry. GeoPharma's competitive advantage lies in its ability to circumvent or overcome the challenges in these markets. For more about GeoPharma, Inc., go to our websites at www.geopharmainc.com, www.hoodiadexL10.com and www.onlineihp.com .
This press release may contain statements, which constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those regarding the company and its subsidiaries' expectations, intentions, strategies and beliefs pertaining to future performance. All statements contained herein are based upon information available to the company's management as of the date hereof, and actual results may vary based upon future events, both within and without management's control. Important factors that could cause such differences are described in the company's periodic filings with the Securities and Exchange Commission.
GeoPharma, Inc.CONTACT: Carol Dore-Falcone, VP/CFO, GeoPharmam Inc., +1-727-544-8866x244, cdf@onlineihp.com; Investor relations: Kevin Nally, Zangani InvestorCommunity, +1-908-788-9660 x625, office@zangani.com
